Ask Orbit
Sales Performance
Sales Performance/Products & Brands

Products & Brands

Portfolio performance across products, brands and therapeutic categories.

1 – 30 Jun 2026·All Divisions·All Regions·All Categories
Demo Data
Orbit Product Briefing
Updated 14 min ago

Cardiaxol remains the strongest growth contributor but is increasingly constrained by supply. Respireze continues to experience excess inventory despite slowing sell-through, while Gastraven shows the highest growth opportunity within underpenetrated territories.

Total Brands
6
3 growing, 3 mature/decline
Total Products
8
+1 launch this quarter
Portfolio Growth
+8.4%
On plan
vs prior year
Top Growth Brand
Gastraven
Momentum
+21.4% YoY
Declining Products
3
Watch
Neurospen, Pulmavent, Metaform
Revenue Contribution
78%
from top 3 brands
Portfolio bubble
Growth × Revenue · size = market contribution
Therapeutic mix
Revenue split by category
Cardiovascular
Respiratory
Gastrointestinal
Neurology
Metabolic
Brand contribution
Revenue and growth by brand
Product lifecycle
Portfolio distribution across stages
Launch
1
R8.1m
Growth
3
R87.6m
Mature
3
R67.9m
Decline
1
R19.3m
Product momentum
Cardiaxol 20mg
Cardiaxol 40mg
Respireze Inhaler
Gastraven 20mg
Gastraven Chewable
Pulmavent DPI
Neurospen 500
Metaform 850
GrowthStockForecast
Risks & opportunities
Prioritised for this period
Risks
Declining respiratory products-R1.2m
Supply constraints on Cardiaxol-R1.6m
Portfolio concentration in top 378% rev
Metaform pricing pressure-R0.4m
Opportunities
Expand Cardiaxol distribution+R1.8m
Increase Gastraven detailing+R1.2m
Refresh declining portfolio+R0.6m
Launch Gastraven Chewable ext.+R0.4m
Cross-page investigation
Follow the commercial thread
Wholesalers & Key Accounts
Where do these products land?
Customers
Who is buying — and who has stopped?
Targets & Forecast
Which products drive the forecast gap?
Inventory & Stock Health
Where are we constrained?
Portfolio detail
Revenue, growth, forecast, stock health and opportunity score
BrandProductRevenueGrowthForecastStockSecondaryRiskOpportunityAction
CardiaxolCardiaxol 20mgR42.8m+24.1%96%LowR21.2mMed92Expedite + expand
CardiaxolCardiaxol 40mgR25.4m+12.4%93%LowR10.4mMed78Confirm supply
RespirezeRespireze InhalerR31.2m+6.6%82%ExcessR9.1mMed58Redistribute
GastravenGastraven 20mgR19.4m+22.3%112%HealthyR7.6mLow94Extend to WC
GastravenGastraven ChewableR8.1m+28.9%118%HealthyR6.1mLow88Scale detailing
PulmaventPulmavent DPIR14.6m-6.8%78%LowR3.6mHigh42Escalate supply
NeurospenNeurospen 500R19.3m-8.4%86%ExcessR2.9mHigh32Reduce inbound
MetaformMetaform 850R22.1m-4.2%91%ExcessR2.4mMed44Refresh promo